Suppr超能文献

一组囊性纤维化患者气道疾病的微生物学研究

Microbiology of airway disease in a cohort of patients with cystic fibrosis.

作者信息

Lambiase Antonietta, Raia Valeria, Del Pezzo Mariassunta, Sepe Angela, Carnovale Vincenzo, Rossano Fabio

机构信息

Department of Biology and Pathology Cellular and Molecular Luigi Califano, University of Naples Federico II, Italy.

出版信息

BMC Infect Dis. 2006 Jan 11;6:4. doi: 10.1186/1471-2334-6-4.

Abstract

BACKGROUND

Recent reports document an increasing incidence of new Gram-negative pathogens such as Stenotrophomonas maltophilia and Alcaligenes xylosoxidans isolated from patients with Cystic Fibrosis, along with an increase in common Gram-negative pathogens such as Pseudomonas aeruginosa and Burkholderia cepacia complex. Furthermore, the increase in multidrug-resistance of such organisms makes the therapeutic management of these patients more problematic. Therefore, careful isolation and identification, and accurate studies of susceptibility to antibiotics are critical for predicting the spread of strains, improving therapeutic measures and facilitating our understanding of the epidemiology of emerging pathogens. The first aim of this study was to determine the incidence and the prevalence of colonization by Gram-negative organisms isolated from respiratory samples of Cystic Fibrosis patients in the Regional Referral Cystic Fibrosis Centre of Naples; the second was to evaluate the spectrum of multidrug-resistance of these organisms.

METHODS

Patients (n = 300) attending the Regional Cystic Fibrosis Unit were enrolled in this study over 3 years. Sputum was processed for microscopic tests and culture. An automated system, Phoenix (Becton Dickinson, Sparks, Maryland, USA), was used for phenotypic identification of all strains; the API 20 NE identification system (bioMérieux, Marcy l'Etoile, France) was used when the identification with the Phoenix system was inaccurate. A PCR-RFLP method was used to characterize the organisms in the Burkholderia cepacia complex. A chemosusceptibility test on microbroth dilutions (Phoenix) was used. Primary outcomes such as FEV1 were correlate with different pathogens.

RESULTS

During the period of study, 40% of patients was infected by Pseudomonas aeruginosa, 7% by Burkholderia cepacia complex, 11% by Stenotrophomonas maltophilia and 7% by Alcaligenes xylosoxidans. Of the strains isolated, 460 were multidrug-resistant. Multiresistant were Pseudomonas aeruginosa and Burkholderia cepacia complex.

CONCLUSION

The results confirm previously reported data; in particular, they show an increase the isolation of non-fermentative Gram-negative bacteria in Cystic Fibrosis patients. They also demonstrate increased resistance to antibiotics. Beta-lactams are rarely effective, with exception of ceftazidime, which is the most efficacious agent against multiresistant strains. Aminoglycosides and quinolones are poorly efficacious.

摘要

背景

最近的报告显示,从囊性纤维化患者中分离出的嗜麦芽窄食单胞菌和木糖氧化产碱杆菌等新型革兰氏阴性病原体的发病率不断上升,同时铜绿假单胞菌和洋葱伯克霍尔德菌复合体等常见革兰氏阴性病原体的发病率也在增加。此外,这些微生物多重耐药性的增加使得对这些患者的治疗管理更加困难。因此,仔细的分离和鉴定以及对抗生素敏感性的准确研究对于预测菌株传播、改进治疗措施以及促进我们对新出现病原体流行病学的理解至关重要。本研究的首要目的是确定那不勒斯地区转诊囊性纤维化中心囊性纤维化患者呼吸道样本中分离出的革兰氏阴性菌的定植发生率和患病率;第二个目的是评估这些微生物的多重耐药谱。

方法

在3年时间里,对该地区囊性纤维化科的300名患者进行了研究。痰液进行了显微镜检查和培养。使用自动化系统Phoenix(美国马里兰州斯帕克斯的贝克顿·迪金森公司)对所有菌株进行表型鉴定;当Phoenix系统鉴定不准确时,使用API 20 NE鉴定系统(法国马西耶图瓦勒的生物梅里埃公司)。采用PCR-RFLP方法对洋葱伯克霍尔德菌复合体中的微生物进行特征分析。使用微量肉汤稀释法(Phoenix)进行药敏试验。将诸如第一秒用力呼气容积(FEV1)等主要结果与不同病原体进行关联分析。

结果

在研究期间,40%的患者感染了铜绿假单胞菌,7%感染了洋葱伯克霍尔德菌复合体,11%感染了嗜麦芽窄食单胞菌,7%感染了木糖氧化产碱杆菌。在分离出的菌株中,460株具有多重耐药性。多重耐药的是铜绿假单胞菌和洋葱伯克霍尔德菌复合体。

结论

结果证实了先前报道的数据;特别是,它们显示囊性纤维化患者中非发酵革兰氏阴性菌的分离率有所增加。它们还表明对抗生素的耐药性增加。β-内酰胺类药物很少有效,除了头孢他啶,它是对抗多重耐药菌株最有效的药物。氨基糖苷类和喹诺酮类药物疗效不佳。

相似文献

1
Microbiology of airway disease in a cohort of patients with cystic fibrosis.
BMC Infect Dis. 2006 Jan 11;6:4. doi: 10.1186/1471-2334-6-4.
2
Chryseobacterium respiratory tract infections in patients with cystic fibrosis.
J Infect. 2007 Dec;55(6):518-23. doi: 10.1016/j.jinf.2007.08.002. Epub 2007 Sep 21.
3
Identification and antimicrobial susceptibility of Alcaligenes xylosoxidans isolated from patients with cystic fibrosis.
J Clin Microbiol. 2001 Nov;39(11):3942-5. doi: 10.1128/JCM.39.11.3942-3945.2001.
4
Emerging and unusual gram-negative infections in cystic fibrosis.
Semin Respir Crit Care Med. 2007 Jun;28(3):312-21. doi: 10.1055/s-2007-981652.
8
Denitrification by cystic fibrosis pathogens - Stenotrophomonas maltophilia is dormant in sputum.
Int J Med Microbiol. 2015 Jan;305(1):1-10. doi: 10.1016/j.ijmm.2014.07.002. Epub 2014 Aug 10.

引用本文的文献

2
Ceftolozane/tazobactam disrupts Pseudomonas aeruginosa biofilms under static and dynamic conditions.
J Antimicrob Chemother. 2025 Feb 3;80(2):372-380. doi: 10.1093/jac/dkae413.
3
Phage therapy to treat cystic fibrosis complex lung infections: perspectives and challenges.
Front Microbiol. 2024 Oct 18;15:1476041. doi: 10.3389/fmicb.2024.1476041. eCollection 2024.
4
7
The Status of Carbapenem Resistance in Cystic Fibrosis: A Systematic Review and Meta-Analysis.
Yale J Biol Med. 2022 Dec 22;95(4):495-506. eCollection 2022 Dec.

本文引用的文献

1
Association between Stenotrophomonas maltophilia and lung function in cystic fibrosis.
Thorax. 2004 Nov;59(11):955-9. doi: 10.1136/thx.2003.017707.
4
Early antibiotic treatment of pseudomonas aeruginosa colonisation in cystic fibrosis: a critical review of the literature.
Eur J Clin Pharmacol. 2004 Apr;60(2):67-74. doi: 10.1007/s00228-004-0735-2. Epub 2004 Mar 5.
5
New concepts of the pathogenesis of cystic fibrosis lung disease.
Eur Respir J. 2004 Jan;23(1):146-58. doi: 10.1183/09031936.03.00057003.
6
Infection control in cystic fibrosis.
Clin Microbiol Rev. 2004 Jan;17(1):57-71. doi: 10.1128/CMR.17.1.57-71.2004.
7
Antibiotic treatment of multidrug-resistant organisms in cystic fibrosis.
Am J Respir Med. 2003;2(4):321-32. doi: 10.1007/BF03256660.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验